US Diabetes Market Report: 2017 - 2022



IMARC’s new report “US Diabetes Market Report: 2017 - 2022” comprehensively discusses the US diabetes market. With more than 27 Million diabetes patients in the US, it represented the world’s third largest diabetes patient pool in 2016. The prevailing cases of diabetes are largely due to rising obesity levels and an increasing aging population. It has been found in the report that more than half of the US population is either obese or overweight which is mainly due to their sedentary lifestyles, physical inactivities and unhealthy eating habits. Furthermore, the aging population in the US has been on the rise since the 1960’s. People aged 65 years and above accounted for around 9% of the total population in 1960 while in 2016, this age group accounted for around 15% of the entire US population. Driven by rising incidences of diabetes and the fact that the US has one of the highest per capita healthcare expenditures, the US market for diabetes drugs has grown at a CAGR of around 13.3% during 2009-2016, reaching a value of US$ 32,783 Million in 2016.

The report has provided analysis of the population and prevalence rates of diabetes on the basis of type, region, gender and age group. The report finds that compared to Type-1 diabetes, Type-2 diabetes represents the more prevalent type, accounting for the majority of all diagnosed diabetes cases. Based on regions, urban areas currently consist of the majority of the diabetes patients as compared to rural areas. Based on gender, females presently account for the majority of the total diabetes patients. In terms of age groups, the age group 40-59 currently accounts for the majority of the total diabetes patients in the US followed by the age group 60-79 and 20-39.

US Diabetes Market

The report has further segmented the US diabetes market according to drug types. The market currently consists of insulin and oral anti-diabetics, with insulin accounting for the majority of the total sales. For each of the two drug types, the report has also provided historical market trends, market breakup by class, key players and market outlook. On the basis of class, Long Acting Insulin represent the biggest class in the insulin market while DPP-IV inhibitors represent the biggest class in the oral anti-diabetics market.

This report provides an analytical and statistical insight into the US diabetes market. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in the United States. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook of the US diabetes market. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the US diabetes market in any form.

US Diabetes Market Report

 

What we have achieved in this report:

Comprehensive situation analysis of the US diabetes epidemiology and its dynamics:

Focus of the Analysis:

  • Historical, current and future prevalence of diabetes in US
  • Historical, current and future prevalence of type-1 and type-2 diabetes in US
  • Historical, current and future prevalence of diabetes in the urban and rural regions in US
  • Historical, current and future prevalence of diabetes among males and females in US
  • Historical, current and future prevalence of diabetes among various age groups in US
  • Historical, current and future diagnosis rates for diabetes in US
  • Historical, current and future drug treatment rates for diabetes in US

 

Comprehensive situation analysis of the US Oral Antidiabetics market and its dynamics:

Focus of the Analysis:

  • Performance of the Oral Antidiabetics market in US
  • Performance of key classes
  • Performance of key players
  • Market outlook

 

Comprehensive situation analysis of the US Insulin market and its dynamics:

Focus of the Analysis:

  • Performance of the Insulin market in US
  • Performance of key classes
  • Performance of key players
  • Market outlook

1 Preface
2 Research Methodology
3 Executive Summary
4 Introduction

    4.1 Overview
    4.2 Key Industry Trends
5 Diabetes Disease Overview
    5.1 What is Diabetes?
    5.2 Diabetes Diagnosis and Treatment
        5.2.1 Diagnosis
        5.2.2 Treatment
    5.3 Diabetes Complications
6 US Diabetes Epidemiology
    6.1 Diabetes Population and Prevalence Rates
    6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
    6.3 Population and Prevalence Rates by Region
    6.4 Population and Prevalence Rates by Gender
    6.5 Population and Prevalence Rates by Age Group
7 US Diabetes Market
    7.1 Market Overview 
    7.2 Market Performance
    7.3 Market Forecast
    7.4 SWOT Analysis
        7.4.1 Strengths
        7.4.2 Weaknesses
        7.4.3 Opportunities
        7.4.4 Threats
    7.5 Value Chain Analysis
    7.6 Porter’s Five Forces Analysis
        7.6.1 Overview
        7.6.2 Bargaining Power of Buyers
        7.6.3 Bargaining Power of Suppliers
        7.6.4 Degree of Competition
        7.6.5 Threat of New Entrants
        7.6.6 Threat of Substitutes
     7.7 Market Breakup by Segment
        7.7.1 US Oral Antidiabetics Market
            7.7.1.1 Historical Market Trends
            7.7.1.2 Market Breakup by Class
            7.7.1.3 Market Shares of Key Players
            7.7.1.4 Market Forecast
        7.7.2 US Insulin Market
            7.7.2.1 Historical Market Trends
            7.7.2.2 Market Breakup by Class
            7.7.2.3 Market Shares of Key Players
            7.7.2.4 Market Forecast
8 Competitive Landscape
    8.1 Competitive Structure
    8.2 Profiles of Key Players
        8.2.1 Merck
        8.2.2 Astra Zeneca
        8.2.3 Novo Nordisk
        8.2.4 Johnson and Johnson
    8.2.5 Others 

List of Figures

Figure 1: The Impact of Diabetes in the Human Body
Figure 2: Diabetes Complications
Figure 3: Global: Breakup of Diabetes Patients by Region, (in %) 2016 & 2035
Figure 4: US: Overweight & Obese Population* (in Million), 2010, 2016 & 2022
Figure 5: Body Mass Index and Relative risk of Type-2 Diabetes
Figure 6: US: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+), (in %)
Figure 7: US: Diabetes Prevalence By Age Groups, (in %)
Figure 8: US: Total Number of Diabetes Patients* (in 000), 2009-2016
Figure 9: US: Total Number of Diabetes Patients* Forecast (in 000), 2017-2022
Figure 10: US (Type1 & Type2): Total Number of Diabetes Patients* (in 000), 2009- 2016
Figure 11: US (Type1 & Type2): Total Number of Diabetes Patients* (in 000), 2017-2022
Figure 12: US (Urban & Rural): Total Number of Diabetes Patients* (in 000), 2009 -2022
Figure 13: US (Urban & Rural): Total Number of Diabetes Patients* (in 000), 2017 - 2022
Figure 14: US (Male & Female): Total Number of Diabetes Patients* (in 000), 2009 - 2016
Figure 15: US (Male & Female): Total Number of Diabetes Patients* (in 000), 2017 - 2022
Figure 16: US: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2009 - 2016
Figure 17: US: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2017 – 2022
Figure 18: US: Diabetes Drug Industry Overview
Figure 19: US: Diabetes Drug Market (in Million US$), 2009 - 2016
Figure 20: US: Diabetes Drug Market Forecast (in Million US$), 2017 – 2022
Figure 21: US: Diabetes Drug Market: SWOT Analysis
Figure 22: US: Diabetes Drug Market: Value Chain Analysis
Figure 23: US: Diabetes Drug Market: Porters Five Forces Analysis
Figure 24: US: Diabetes Drug Market: Breakup of Insulin and Oral Antidiabetics (in %), 2009 - 2016
Figure 25: US: Diabetes Drug Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2017 - 2022
Figure 26: US: Oral Antidiabetics Market: (in Million US$), 2009 - 2016
Figure 27: US: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2009 & 2016
Figure 28: US: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
Figure 29: US: Oral Antidiabetics Market: (in Million US$), 2017 - 2022
Figure 30: US: Insulin Market, (in Million US$), 2009 - 2016
Figure 31: US: Breakup of Insulin Market by Class (in %)
Figure 32: US: Insulin Market: Sales Share of Key Players (in %)
Figure 33: US: Insulin Market Forecast (in Million US$), 2017 - 2022


 List of Tables

Table 1: Diagnosis of Diabetes
Table 2: Global: Diabetes Population Breakup by Country (in 000’s), 2016 & 2035
Table 3: US: Overweight & Obesity Statistics, 2010, 2016 & 2022
Table 4: US: Breakup of Total Population by Age Groups (0-14, 15-64 & 65+), (in Million)
Table 5: US: Total Prevalence & Number of Diabetes Patients*, 2009, 2016 & 2022
Table 6: US (Type1 & Type2): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
Table 7: US (Urban & Rural): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
Table 8: US (Male & Female): Total Prevalence & Number of Diabetes Patients, 2009, 2016 & 2022
Table 9: US: Total Prevalence & Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (In Millions), 2009, 2016 & 2022
Table 10: US: Diabetes Drug Market: Competitive Structure 


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Special Prices


    IMARC provides special pricing for:

  • Academic Institutes
  • Government Agencies
  • Nonprofit Organizations
  • For more information, feel free to contact us.






Related Report

GCC Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022

According to IMARC Group’s latest report titled “GCC Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022”, the generic drugs market in the GCC reached a value of nearly US$ 1,550 Million in 2016, exhibiting a CAGR of 15% during 2009-2016.


US Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022

According to IMARC Group’s new report titled “US Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022”, the US generic injectables market reached a value of US$ 10 Billion in 2016, exhibiting a CAGR of more than 9% during 2009-2016.


Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022

According to IMARC Group’s latest report titled, “Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022”, the global generic injectables market reached a value of more than US$ 23 Billion in 2016, exhibiting a CAGR of around 9% during 2009-...


Global Biopharmaceutical Manufacturing Market Report 2017-2021

IMARC Group’s latest report titled “Global Biopharmaceutical Manufacturing Market Report 2017-2021” provides a detailed analysis on the global biopharmaceutical manufacturing industry. Biopharmaceuticals represent one of the most elegant and sophisticated achievements of modern science. Compar...


Global Biopharmaceutical Market Report & Forecast (2017-2021)

IMARC’s new report “Global Biopharmaceutical Market Report & Forecast (2017-2021)” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market tre...